Last reviewed · How we verify

Neoplasm of prostate — Treatment Landscape & Competitive Intelligence

Neoplasm of prostate (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neoplasm of prostate, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Eulexin flutamide Pfizer Inc. Androgen Receptor Inhibitor [EPC] Androgen receptor 1989-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Neoplasm of prostate
  2. Pfizer Inc. · 1 drug in Neoplasm of prostate

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neoplasm of prostate:

Cite this brief

Drug Landscape (2026). Neoplasm of prostate — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neoplasm-of-prostate. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing